129 related articles for article (PubMed ID: 36778347)
21. Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts.
Van Langenhove T; van der Zee J; Engelborghs S; Vandenberghe R; Santens P; Van den Broeck M; Mattheijssens M; Peeters K; Nuytten D; Cras P; De Deyn PP; De Jonghe P; Cruts M; Van Broeckhoven C
Neurobiol Aging; 2012 May; 33(5):1004.e17-20. PubMed ID: 22035589
[TBL] [Abstract][Full Text] [Related]
22. TDP-43 levels in the brain tissue of ALS cases with and without
Yang Y; Halliday GM; Kiernan MC; Tan RH
Neurology; 2019 Nov; 93(19):e1748-e1755. PubMed ID: 31619481
[TBL] [Abstract][Full Text] [Related]
23. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?
van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ
Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266
[TBL] [Abstract][Full Text] [Related]
24. Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions.
Watanabe R; Higashi S; Nonaka T; Kawakami I; Oshima K; Niizato K; Akiyama H; Yoshida M; Hasegawa M; Arai T
Acta Neuropathol Commun; 2020 Oct; 8(1):176. PubMed ID: 33115537
[TBL] [Abstract][Full Text] [Related]
25. Neuronal models of TDP-43 proteinopathy display reduced axonal translation, increased oxidative stress, and defective exocytosis.
Pisciottani A; Croci L; Lauria F; Marullo C; Savino E; Ambrosi A; Podini P; Marchioretto M; Casoni F; Cremona O; Taverna S; Quattrini A; Cioni JM; Viero G; Codazzi F; Consalez GG
Front Cell Neurosci; 2023; 17():1253543. PubMed ID: 38026702
[TBL] [Abstract][Full Text] [Related]
26. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS.
Bonini NM; Gitler AD
J Mol Neurosci; 2011 Nov; 45(3):676-83. PubMed ID: 21660502
[TBL] [Abstract][Full Text] [Related]
27. Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis.
Figley MD; Thomas A; Gitler AD
Neurobiol Aging; 2014 Apr; 35(4):936.e1-4. PubMed ID: 24269018
[TBL] [Abstract][Full Text] [Related]
28. Polyglutamine tracts regulate beclin 1-dependent autophagy.
Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
[TBL] [Abstract][Full Text] [Related]
29. Nuclear depletion of RNA-binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis.
Diaz-Garcia S; Ko VI; Vazquez-Sanchez S; Chia R; Arogundade OA; Rodriguez MJ; Traynor BJ; Cleveland D; Ravits J
Acta Neuropathol; 2021 Dec; 142(6):985-1001. PubMed ID: 34618203
[TBL] [Abstract][Full Text] [Related]
30. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS).
Volkening K; Leystra-Lantz C; Yang W; Jaffee H; Strong MJ
Brain Res; 2009 Dec; 1305():168-82. PubMed ID: 19815002
[TBL] [Abstract][Full Text] [Related]
31. TDP-43 transports ribosomal protein mRNA to regulate axonal local translation in neuronal axons.
Nagano S; Jinno J; Abdelhamid RF; Jin Y; Shibata M; Watanabe S; Hirokawa S; Nishizawa M; Sakimura K; Onodera O; Okada H; Okada T; Saito Y; Takahashi-Fujigasaki J; Murayama S; Wakatsuki S; Mochizuki H; Araki T
Acta Neuropathol; 2020 Nov; 140(5):695-713. PubMed ID: 32803350
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-183-5p regulates TAR DNA-binding protein 43 neurotoxicity via SQSTM1/p62 in amyotrophic lateral sclerosis.
Kim HC; Zhang Y; King PH; Lu L
J Neurochem; 2023 Mar; 164(5):643-657. PubMed ID: 36527420
[TBL] [Abstract][Full Text] [Related]
33. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis.
Suk TR; Rousseaux MWC
Mol Neurodegener; 2020 Aug; 15(1):45. PubMed ID: 32799899
[TBL] [Abstract][Full Text] [Related]
34. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.
Yu Z; Zhu Y; Chen-Plotkin AS; Clay-Falcone D; McCluskey L; Elman L; Kalb RG; Trojanowski JQ; Lee VM; Van Deerlin VM; Gitler AD; Bonini NM
PLoS One; 2011 Mar; 6(3):e17951. PubMed ID: 21479228
[TBL] [Abstract][Full Text] [Related]
35. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
Glass JD; Dewan R; Ding J; Gibbs JR; Dalgard C; Keagle PJ; Shankaracharya ; García-Redondo A; Traynor BJ; Chia R; Landers JE
Brain; 2022 Aug; 145(8):2671-2676. PubMed ID: 35521889
[TBL] [Abstract][Full Text] [Related]
36. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth.
Fallini C; Bassell GJ; Rossoll W
Hum Mol Genet; 2012 Aug; 21(16):3703-18. PubMed ID: 22641816
[TBL] [Abstract][Full Text] [Related]
37. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS).
Nihei Y; Ito D; Suzuki N
J Biol Chem; 2012 Nov; 287(49):41310-23. PubMed ID: 23048034
[TBL] [Abstract][Full Text] [Related]
38. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis.
Chen Y; Huang R; Yang Y; Chen K; Song W; Pan P; Li J; Shang HF
Neurobiol Aging; 2011 Oct; 32(10):1925.e1-5. PubMed ID: 21741123
[TBL] [Abstract][Full Text] [Related]
39. The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway.
Ciura S; Sellier C; Campanari ML; Charlet-Berguerand N; Kabashi E
Autophagy; 2016 Aug; 12(8):1406-8. PubMed ID: 27245636
[TBL] [Abstract][Full Text] [Related]
40. Co-deposition of SOD1, TDP-43 and p62 proteinopathies in ALS: evidence for multifaceted pathways underlying neurodegeneration.
Trist BG; Fifita JA; Hogan A; Grima N; Smith B; Troakes C; Vance C; Shaw C; Al-Sarraj S; Blair IP; Double KL
Acta Neuropathol Commun; 2022 Aug; 10(1):122. PubMed ID: 36008843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
